Feasibility of Using Thrombin Generation Assay (TGA) for Monitoring Bypassing Agent Therapy in Patients With Hemophilia Having Inhibitors

Abstract

In conclusion, we found that the clinical effectiveness of bypass therapy in hemophilia cannot be assessed by TGA and TEG.

A Comparison of Efficacy Between Recombinant Activated Factor VII (Aryoseven) and Novoseven in Patients With Hereditary FVIII Deficiency With Inhibitor

“…56 The expert suggests that therapy of bleeding episodes in patients with FVIII inhibitor by rFVIIa has faster response compared to aPCC. [55][56][57][58][59] In this study, baseline characteristics of patients were comparable to other studies considering the age, bleeding severity and FVII levels before and after intervention, and FVIII inhibitor plasma level. 9,14,56 The number of patients with hemophilia having inhibitor who were treated in most reported trials varied from 15 to 62; in the current study, the sample size was 66 patients.…”

“…We checked mean levels of FVII before and after administration of the 2 rFVIIa preparations to prove FVII: C level was comparably increased. 6,38 In the previous studies, the rate of reported adverse events was 1% to 10%, [50][51][52][53][54][55][56][57][58][59][60] and the most of adverse events had been headache, rashes, hypertension, and rarely thrombosis. We did not encounter any thrombosis in either treatment groups.…”

“…The modern treatment regimens in hemophilia with inhibitor help to decrease bleeding episodes, morbidity, and improve quality of life. [55][56][57][58][59][60][61][62][63][64] New therapeutic strategies are relatively expensive, and they are not affordable for underdeveloped and poor countries. 40,[64][65][66][67] Biosimilar products are comparable hemostatic agents to the branded product and provide better care and wider affordability.…”

“…to270 mg/kg, 2 hours apart, and have been used. We chose 90 to 120 mg/kg dosage, which is similar to other studies 21,[58][59][60][61][62][63][64]. Efficacy and reduction in bleeding were similar in both treatment groups.…”

The use of thromboelastography, thrombin generation test and clotting tests to evaluate the efficacy of hemostatic therapy with recombinant activated factor VII in hemophilia patients with inhibitor

“…Отношение к использованию этих интегральных тестов для мониторинга действия rFVIIa в литературе неоднозначное. При обследова-нии 7 больных с ингибиторной формой гемофилии, получавших шунтирующие препараты (rFVIIa, акти-вированный протромбиновый комплекс), не выявле-но связи между клиническим ответом на их введение и изменениями, регистрируемыми с помощью ТЭГ или теста генерации тромбина [12]. В то же время в многоцентровом исследовании введение rFVIIa в дозе 90 мкг/кг, т. е. в той же дозе, что и в нашем ис-следовании, проводило к нормализации параметров ТЭГ у больных с ингибиторной формой гемофилии [13].…”